Pomalidomide

• CAT Number: A000692
• CAS Number: 19171-19-8
• Molecular Formula: C13H11N3O4
• Molecular Weight: 273.2
• Purity: ≥95%
• Target: TNF-α
• Solubility: >7.5mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
• InChI: 1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
• InChIKey: UVSMNLNDYGZFPF-UHFFFAOYSA-N
• SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

Pomalidomide (CAS 19171-19-8), also known as CC4047, is an orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). Pomalidomide was approved on February 8, 2013 as a treatment for relapsed and refractory multiple myeloma.

Overview of Clinical Research

Pomalidomide is an angiogenesis inhibitor and an immunomodulator developed by Celgene Corporation. Amgen initiates phase II select trial for multiple myeloma therapy in USA, Spain, Denmark, Greece, Italy and Germany. 

Reference

1: Institute for Quality and Efficiency in Health Care. Pomalidomide — Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Dec 23. Available from http://www.ncbi.nlm.nih.gov/books/NBK458414/ PubMed PMID: 29144679.
2: Institute for Quality and Efficiency in Health Care. Pomalidomide (Addendum to Commission A15-42) [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2016 Feb 24. Available from http://www.ncbi.nlm.nih.gov/books/NBK458433/ PubMed PMID: 29144641.
3: Hoy SM. Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma. Drugs. 2017 Nov;77(17):1897-1908. doi: 10.1007/s40265-017-0833-y. PubMed PMID: 29110190.
4: Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, Distler JHW, Korish S, Cooper A, Choi S, Schafer PH, Horan G, Hough DR. Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. J Rheumatol. 2017 Nov 1. pii: jrheum.161040. doi: 10.3899/jrheum.161040. [Epub ahead of print] PubMed PMID: 29093152.
5: Büyükkaramikli NC, de Groot S, Fayter D, Wolff R, Armstrong N, Stirk L, Worthy G, Albuquerque de Almeida F, Kleijnen J, Al MJ. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. Pharmacoeconomics. 2017 Oct 31. doi: 10.1007/s40273-017-0581-6. [Epub ahead of print] Review. PubMed PMID: 29086363.
6: Spencer A, Harrison S, Zonder J, Badros A, Laubach J, Bergin K, Khot A, Zimmerman T, Chauhan D, Levin N, MacLaren A, Reich SD, Trikha M, Richardson P. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14987. [Epub ahead of print] PubMed PMID: 29076150.
7: Scott A, Weber N, Tiley C, Taylor K, Taper J, Harrison S, Chan KL, Stark R, Lee C, Morris K, Ho PJ, Dodds A, Ramanathan S, Ramakrishna R, Watson AM, Auguston B, Kwok F, Quach H, Warburton P, Rowlings P, Mollee P. /'Real-world/' Australian experience of pomalidomide for relapsed and refractory myeloma. Leuk Lymphoma. 2017 Oct 12:1-3. doi: 10.1080/10428194.2017.1387911. [Epub ahead of print] PubMed PMID: 29022836.
8: Pelligra CG, Parikh K, Guo S, Chandler C, Mouro J, Abouzaid S, Ailawadhi S. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States. Clin Ther. 2017 Oct;39(10):1986-2005.e5. doi: 10.1016/j.clinthera.2017.08.010. Epub 2017 Sep 28. PubMed PMID: 28967482.
9: Davis DA, Mishra S, Anagho HA, Aisabor AI, Shrestha P, Wang V, Takamatsu Y, Maeda K, Mitsuya H, Zeldis JB, Yarchoan R. Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. Oncotarget. 2017 May 17;8(31):50342-50358. doi: 10.18632/oncotarget.17960. eCollection 2017 Aug 1. PubMed PMID: 28881567; PubMed Central PMCID: PMC5584136.
10: Seki JT, Sakurai N, Lam W, Reece DE. Pomalidomide desensitization in a patient hypersensitive to immunomodulating agents. Curr Oncol. 2017 Aug;24(4):e328-e332. doi: 10.3747/co.24.3572. Epub 2017 Aug 31. PubMed PMID: 28874903; PubMed Central PMCID: PMC5576472.